Navigation Links
Alzheimer's Drug Discovery Foundation Presents its 8th Annual Drug Discovery for Neurodegeneration Conference in February 2014
Date:12/5/2013

NEW YORK, Dec. 5, 2013 /PRNewswire-USNewswire/ -- The Alzheimer's Drug Discovery Foundation (ADDF) presents its annual winter conference, the 8th Annual Drug Discover for Neurodegeneration Conference: An Intensive Course on Translating Research into Drugs, taking place on February 2-4, 2014 at the Miami Beach Resort in Miami, Florida.

(Logo: http://photos.prnewswire.com/prnh/20130909/DC75486LOGO)

Designed as a comprehensive course on the drug discovery process, from target validation through to clinical development, the annual Drug Discovery for Neurodegeneration conference provides participants with the fundamental knowledge and resources to translate their research into new drugs to treat and prevent Alzheimer's disease and related neurodegenerative diseases. 
 
Attendees from academia and industry will also learn from specific case studies examples and will have an opportunity to engage in interactive discussions on securing partnerships. The program will include a focus on Alzheimer's disease, Parkinson's disease and Multiple Sclerosis.

For more information about this conference, sponsorship opportunities, or to register please visit our conference website or contact Sara Classen, Manager of Scientific Conferences & Meetings at sclassen@alzdiscovery.org or 212-901-8009.

About the Alzheimer's Drug Discovery Foundation (www.AlzDiscovery.org)

The mission of the Alzheimer's Drug Discovery Foundation (ADDF) is to accelerate the discovery of drugs to prevent, treat and cure Alzheimer's disease, related dementias and cognitive aging. The ADDF has granted more than $60 million to fund almost 400 Alzheimer's drug discovery programs in academic centers and biotechnology companies in 18 countries.


'/>"/>
SOURCE Alzheimer's Drug Discovery Foundation
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Discovery, Preclinical and Clinical Stage Partnering Terms and Agreements in Pharma and Biotech
2. Alzheimers Drug Discovery Foundation Expands its ADDF ACCESS Program to Improve Quality and Efficiency of Drug Research for Neurodegenerative Diseases
3. Exosome Diagnostics Enters Collaboration Agreement with Lilly for Exosome Blood-Based Biomarker Discovery
4. Berg Receives Frost & Sullivan 2013 Drug Discovery Technology Innovation Award
5. Metabolic Solutions Development Company presents Phase 2a clinical trial results at the 14th International Conference on Alzheimers Drug Discovery
6. KemPharm Continues to Expand its Pain Therapy Pipeline with Discovery of KP606, a Novel Prodrug of Oxycodone
7. Novel Use of Pressure BioSciences Patented PCT Platform Offers New Insights into Protein Structure and Function, New Tool for Biomarker Discovery and Rational Drug Design
8. Alzheimers Drug Discovery Foundation Supports Madera Biosciences to Advance Small Molecule Drugs that Upregulate apoE
9. Discovery Labs Presents Final Assessment in a Series of Pharmacoeconomic Analyses that Explore Impact of Reintubation on Healthcare Costs
10. Quantum Materials Tetrapod Quantum Dots Break Kashas Rule: Enhanced Performance Enables Commercialization of Novel Discovery
11. Novira Therapeutics Expands Management Team with Appointment of Klaus Klumpp, Ph.D., the Former Global Head of Roches Virology Discovery Initiatives, as Vice President Discovery Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... , Dec. 8, 2016   TriNetX ... Nationwide Children,s Hospital signed a membership ... accelerate the development of new cures. ... representing over 57 million patients globally, biopharmaceutical companies ... together to improve protocol design, site selection, patient ...
(Date:12/8/2016)... HARRISBURG, Pa. , Dec. 8, 2016 /PRNewswire-USNewswire/ ... and Secretary of Drug and Alcohol Programs ... anxiety and insomnia medications, known as benzodiazepines, developed ... "Benzodiazepines are medications that are frequently ... "However, when they are used with opioid pain ...
(Date:12/8/2016)... 2016  A new study by a pair of ... opioid therapy to treat chronic pain is not only ... harmful consequences, including death. Palliative care physicians ... Mehta , M.D., authored the study which provides a ... The study was published in the December 2016 edition ...
Breaking Medicine Technology:
(Date:12/9/2016)... ... December 09, 2016 , ... The Justin Veatch ... Inc. (NCADD) is recommending the film Whispering Spirits and its discussion ... of Columbia as an education tool in the war against teen drug abuse. ...
(Date:12/9/2016)... NJ (PRWEB) , ... December 09, 2016 , ... ... Founders Ball at The Pierre Hotel in New York, NY, on December 3rd, ... benefactors, dignitaries and physicians attended the annual event, which raised over $1 million ...
(Date:12/8/2016)... ... December 08, 2016 , ... The West Virginia Medical ... 2017. The name change aligns the entire company with its existing Quality ... quality. , “We are very proud of the achievements associated with the West ...
(Date:12/8/2016)... ... 08, 2016 , ... ZyDoc , a New York-based ... Data Capture Methods for Input to Electronic Health Records: A Comparative Usability Study” ... comparative usability study demonstrate that a dictation-based method (“NLP Entry”) using ZyDoc’s MediSapien™ ...
(Date:12/8/2016)... ... December 08, 2016 , ... With the increasing demand ... “What’s In Your Mouth?” (WIYM) campaign to inform dentists and patients about the safety ... dental implant and prosthetic market in the U.S. is projected to reach $6.4 billion ...
Breaking Medicine News(10 mins):